Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Elit

Showing results (61-70 of 62) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 62 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2011
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-studyJ E Kurtz, M C Kaminsky, A Floquet, et al.
Journal of the National Cancer Institute|October 13, 2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxelP Hoskins, I Vergote, A Cervantes, et al.
Pageof 7

Showing results (61-70 of 62) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 62 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2011
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-studyJ E Kurtz, M C Kaminsky, A Floquet, et al.
Journal of the National Cancer Institute|October 13, 2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxelP Hoskins, I Vergote, A Cervantes, et al.
Pageof 7